Kerry has extensive expertise in drug discovery, primarily within the neuroscience and oncology disease areas. She has previously held roles at AstraZeneca and the DNA repair biotech company, KuDOS Pharmaceuticals, where she led oncology drug discovery projects from target identification through to candidate drug selection. At MDC she established a cell models capability in neuroscience before moving to her current role where she specialises in identifying and profiling molecular biomarkers of neurodegenerative diseases.
Dr Kerry Shea
Lead Scientist
